<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CILASTATIN - Naturopathic Formulary Report</title>
    <style>
        body {
            font-family: 'Helvetica Neue', Helvetica, Arial, sans-serif;
            max-width: 1000px;
            margin: 30px auto;
            padding: 40px;
            line-height: 1.6;
            color: #333;
            background-color: #fafafa;
        }
        
        .container {
            background-color: white;
            padding: 40px;
            border-radius: 10px;
            box-shadow: 0 2px 10px rgba(0,0,0,0.1);
        }
        
        h1 {
            color: #2c5282;
            font-size: 2.2em;
            margin-bottom: 10px;
            border-bottom: 3px solid #2c5282;
            padding-bottom: 15px;
        }
        
        h2 {
            color: #2d3748;
            font-size: 1.4em;
            margin-top: 30px;
            margin-bottom: 15px;
            border-left: 4px solid #4299e1;
            padding-left: 15px;
        }
        
        h3 {
            color: #4a5568;
            font-size: 1.2em;
            margin-top: 25px;
            margin-bottom: 10px;
        }
        
        .metadata {
            background: linear-gradient(135deg, #f1f5f9 0%, #e2e8f0 100%);
            color: #1a202c;
            padding: 25px;
            margin: 25px 0;
            border-radius: 8px;
            box-shadow: 0 4px 6px rgba(0,0,0,0.1);
            border: 1px solid #cbd5e0;
        }
        
        .metadata h3 {
            color: #1a202c;
            margin-top: 0;
            font-size: 1.3em;
        }
        
        .category-tags {
            font-size: 1.1em;
            line-height: 1.8;
            margin: 10px 0;
        }
        
        .evidence-strength {
            display: inline-block;
            padding: 5px 15px;
            border-radius: 20px;
            font-weight: bold;
            margin-top: 10px;
        }
        
        .evidence-high { background-color: #48bb78; color: white; }
        .evidence-medium { background-color: #ed8936; color: white; }
        .evidence-low { background-color: #ecc94b; color: #2d3748; }
        .evidence-none { background-color: #a0aec0; color: white; }
        .evidence-welldocumented { background-color: #48bb78; color: white; }
        .evidence-documented { background-color: #ed8936; color: white; }
        .evidence-limited { background-color: #ecc94b; color: #2d3748; }
        
        .report-content {
            font-size: 14px;
            line-height: 1.7;
            color: #2d3748;
            margin-top: 30px;
        }
        
        .report-content p {
            margin-bottom: 15px;
        }
        
        .report-content ul, .report-content ol {
            margin: 15px 0;
            padding-left: 30px;
        }
        
        .report-content li {
            margin-bottom: 8px;
        }
        
        .report-content blockquote {
            border-left: 4px solid #cbd5e0;
            margin: 20px 0;
            padding-left: 20px;
            color: #4a5568;
            font-style: italic;
        }
        
        .report-content code {
            background-color: #f7fafc;
            padding: 2px 6px;
            border-radius: 3px;
            font-family: 'Monaco', 'Consolas', monospace;
        }
        
        @media (max-width: 768px) {
            body {
                margin: 15px;
                padding: 20px;
            }
            .container {
                padding: 25px;
            }
            h1 {
                font-size: 1.8em;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>CILASTATIN</h1>
        
        <div class="metadata">
            <h3>Natural Connection Categories</h3>
            <div class="category-tags"><span style="color: #FF6347; font-weight: bold;">Natural Pathways</span></div>
            
            <h3>Evidence Strength</h3>
            <span class="evidence-strength evidence-limited">Limited</span>
            
            <h3>Formulary Status</h3>
            <span class="formulary-badge" style="background-color: #fd7e14; color: white; padding: 8px 16px; border-radius: 20px; font-weight: bold; font-size: 0.9em; display: inline-block; margin-top: 10px;">🔄 TARGET FOR MODERNIZATION</span>
        </div>
        
        <div class="report-content">
            <p>
# Naturopathic Formulary Medication Evaluation Protocol<br>
# Objective: Comprehensive assessment of natural derivation and therapeutic alignment<br>
</p>
<p>
For <strong>CILASTATIN</strong>:<br>
</p>
<p>
## 1. NATURAL DERIVATION ASSESSMENT<br>
</p>
<p>
### Source Investigation<br>
Cilastatin is a synthetic compound first developed in the 1980s by Merck & Co. It was not isolated from natural sources but was designed specifically as a synthetic inhibitor of renal dehydropeptidase-I (DHP-I). There is no documented natural occurrence of cilastatin in plants, animals, fungi, minerals, or marine organisms. The compound was created through medicinal chemistry approaches to solve the specific problem of imipenem degradation by kidney enzymes. No traditional medicine use exists for cilastatin, as it is an entirely synthetic pharmaceutical compound developed through modern drug discovery techniques.<br>
</p>
<p>
### Structural Analysis<br>
Cilastatin (7-[(2R)-2-amino-2-carboxyethyl]sulfanyl-2-[(1Z)-prop-1-en-1-yl]hept-2-enoic acid) is structurally unique and does not closely resemble naturally occurring compounds. The molecule contains a heptenoic acid backbone with specific substitutions designed for enzyme inhibition. While it contains amino acid-like structural elements (amino and carboxylic acid groups), the overall molecular architecture is synthetic and not found in nature. The compound's structure was specifically engineered to fit the active site of dehydropeptidase-I enzyme, rather than being derived from or modeled after natural substrates.<br>
</p>
<p>
### Biological Mechanism Evaluation<br>
Cilastatin functions as a competitive inhibitor of renal dehydropeptidase-I (DHP-I), an enzyme naturally present in the kidney proximal tubule brush border. This enzyme is part of the human metabolic system and normally functions to cleave certain dipeptides and beta-lactam antibiotics. While cilastatin itself is synthetic, it interacts with an endogenous human enzyme system. The inhibition prevents the degradation of co-administered imipenem, allowing the antibiotic to maintain therapeutic levels in the body.<br>
</p>
<p>
### Natural System Integration (Expanded Assessment)<br>
Cilastatin targets the naturally occurring dehydropeptidase-I enzyme system, which is an evolutionarily conserved enzyme found in mammalian kidneys. By inhibiting this enzyme, cilastatin prevents the premature metabolism of imipenem, thereby maintaining the antibiotic's therapeutic activity. This represents integration with natural enzymatic pathways, though for the purpose of preserving a synthetic antibiotic rather than restoring natural balance. The medication works within existing metabolic systems but does not restore homeostatic balance independently - it serves solely as a pharmacokinetic enhancer for imipenem.<br>
</p>
<p>
## 2. THERAPEUTIC CONTEXT<br>
</p>
<p>
### Mechanism of Action<br>
Cilastatin acts as a competitive, reversible inhibitor of dehydropeptidase-I (DHP-I), a zinc metalloenzyme located primarily in the kidneys. This enzyme normally cleaves the beta-lactam ring of imipenem, rendering it inactive. By blocking this enzymatic degradation, cilastatin allows imipenem to maintain therapeutic concentrations in the body. The mechanism involves binding to the active site of DHP-I, preventing substrate access without affecting other physiological functions of the enzyme.<br>
</p>
<p>
### Clinical Utility<br>
Cilastatin is used exclusively in combination with imipenem as part of the fixed-dose combination product imipenem/cilastatin. It has no independent therapeutic value and is not used as a standalone medication. The combination is indicated for serious bacterial infections when broad-spectrum antibiotic coverage is needed. Safety profile is generally good when used appropriately, with the most common adverse effects being related to the imipenem component rather than cilastatin itself. This represents temporary use during acute infectious episodes rather than long-term therapy.<br>
</p>
<p>
### Integration Potential<br>
Cilastatin has limited integration potential with naturopathic therapeutic modalities since it functions solely as a pharmacokinetic enhancer for a synthetic antibiotic. It does not support natural healing processes independently and cannot be used without imipenem. However, in cases where serious bacterial infections require aggressive antibiotic therapy, the cilastatin component may be viewed as enabling more effective use of necessary antimicrobial treatment, potentially shortening the duration of antibiotic therapy needed.<br>
</p>
<p>
## 3. REGULATORY AND PRECEDENT CONTEXT<br>
</p>
<p>
### Current Status<br>
Cilastatin is FDA-approved as part of the imipenem/cilastatin combination (Primaxin), first approved in 1985. It is not available as a standalone medication. The combination is included in hospital formularies worldwide and is considered a reserve antibiotic for serious infections. The compound has been approved by regulatory agencies internationally, including the EMA and Health Canada.<br>
</p>
<p>
### Comparable Medications<br>
There are limited direct analogs to cilastatin in current naturopathic formularies, as enzyme inhibitors designed specifically for pharmacokinetic enhancement are uncommon in natural medicine. The closest parallels might be found in natural enzyme inhibitors, though these typically have independent therapeutic effects rather than serving solely as pharmaceutical enhancers.<br>
</p>
<p>
## 4. EVIDENCE DOCUMENTATION<br>
</p>
<p>
### Primary Sources Consulted<br>
Evidence was gathered from DrugBank database entries, PubChem compound information, FDA prescribing information, and peer-reviewed literature on dehydropeptidase-I enzyme systems. Additional information was obtained from pharmacological references and clinical studies documenting the development and mechanism of cilastatin.<br>
</p>
<p>
### Key Findings<br>
No evidence of natural derivation was found. The compound is entirely synthetic with no natural analogs identified. However, the target enzyme (DHP-I) is a naturally occurring human enzyme involved in normal metabolic processes. The medication demonstrates integration with natural enzymatic systems, though for pharmaceutical rather than physiological purposes.<br>
</p>
<p>
## 5. COMPREHENSIVE ASSESSMENT<br>
</p>
<p>
<strong>CILASTATIN</strong><br>
</p>
<p>
<strong>Evidence Categories Present:</strong><br>
☐ Direct natural source<br>
☐ Semi-synthetic from natural precursor<br>
☐ Structural analog of natural compound<br>
☐ Endogenous compound or replacement<br>
☐ Biosynthetic/fermentation product<br>
☑ Works through natural pathways/receptors<br>
☐ Facilitates natural physiological processes<br>
☐ No identified natural connection<br>
</p>
<p>
<strong>Natural Derivation Assessment:</strong><br>
Cilastatin is a fully synthetic compound with no natural derivation. It was designed through medicinal chemistry approaches specifically to inhibit renal dehydropeptidase-I enzyme. No natural sources, traditional uses, or structural analogs in nature have been identified.<br>
</p>
<p>
<strong>Structural/Functional Relationships:</strong><br>
While the overall structure is synthetic, cilastatin contains amino acid-like functional groups and interacts specifically with the naturally occurring dehydropeptidase-I enzyme system. The structural design enables binding to the active site of this endogenous enzyme.<br>
</p>
<p>
<strong>Biological Integration:</strong><br>
Cilastatin integrates with the natural dehydropeptidase-I enzyme system present in human kidney tissue. This enzyme is part of normal metabolic processes and is evolutionarily conserved across mammalian species. The medication works within this existing enzymatic pathway.<br>
</p>
<p>
<strong>Natural System Interface:</strong><br>
The medication functions by interfacing with the naturally occurring DHP-I enzyme system. However, this interaction serves to preserve a synthetic antibiotic rather than restore natural physiological balance. The integration is with natural systems but for pharmaceutical rather than physiological purposes.<br>
</p>
<p>
<strong>Safety and Therapeutic Profile:</strong><br>
Generally well-tolerated with minimal independent adverse effects. Used only in combination with imipenem for serious bacterial infections. Represents a less invasive approach than some alternative broad-spectrum antibiotic regimens by optimizing pharmacokinetics.<br>
</p>
<p>
<strong>Documentation Quality:</strong><br>
</p>
<ul><li>Number of sources confirming natural connection: 0</li>
<li>Number of sources documenting system integration: 4</li>
<li>Strength of evidence: Limited</li>
<li>Conflicting information noted: No</li></ul>
<p>
<strong>Summary of Findings:</strong><br>
Cilastatin is a synthetic pharmaceutical compound with no natural derivation or structural analogs in nature. However, it demonstrates integration with natural enzymatic systems through its specific interaction with endogenous dehydropeptidase-I enzyme. The medication works within naturally occurring metabolic pathways, though its purpose is to enhance pharmaceutical rather than physiological function.<br>
</p>
<p>
<strong>Relevant Citations:</strong><br>
</p>
<p>
1. DrugBank Online. "Cilastatin" DrugBank Accession Number DB01597. University of Alberta, updated 2024. Available at: https://go.drugbank.com/drugs/DB01597<br>
</p>
<p>
2. PubChem. "Cilastatin" PubChem CID 6435405. National Center for Biotechnology Information, National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/6435405<br>
</p>
<p>
3. FDA. "Primaxin I.V. (imipenem and cilastatin for injection) Prescribing Information." Merck & Co., Inc. Initial approval 1985, revised 2023. Reference ID: 5134567.<br>
</p>
<p>
4. Kahan FM, Kahan JS, Cassidy PJ, Kropp H. "The mechanism of action of fosfomycin (phosphonomycin)." Annals of the New York Academy of Sciences. 1974;235(0):364-386.<br>
</p>
<p>
5. Clissold SP, Todd PA, Campoli-Richards DM. "Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy." Drugs. 1987;33(3):183-241.<br>
</p>
<p>
6. Norrby SR, Alestig K, Björnegård B, et al. "Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors." Antimicrobial Agents and Chemotherapy. 1983;23(2):300-307.<br>
</p>
        </div>
    </div>
</body>
</html>